

State of Oklahoma SoonerCare SoonerSelect → ◆aetna Zepzelca[™] (Lurbinectedin) Prior Authorization Form

Member Name:	_ Date of Birth	n: Member ID#:
Drug Information		
Physician billing (HCPCS code:) □	Pharmacy billing (NDC:)
Dose:Regimen:		Start Date (or date of next dose):
Billing Provider Information		
Provider NPI:	Provider	r Name:
Provider Phone:	Prov	rider Fax:
Prescriber Information		
Prescriber NPI:	Prescriber Nar	me:
Prescriber Phone: Pres	criber Fax:	Specialty:
Criteria		
 Small Cell Lung Cancer (SCLC) A. Is diagnosis metastatic SCLC? Yes No B. Will lurbinectedin be used following disease progression on or after platinum-based chemotherapy? Yes No If answer is none of the above, please indicate diagnosis: Additional Information: 		
 For Continued Authorization: 1. Date of last dose: 2. Does member have any evidence of providence of	-	ease while on lurbinectedin therapy? s related to lurbinectedin therapy? Yes No
Additional Information:		
Prescriber Signature:	medically nec	Date:

the best of my knowledge.

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts.All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.